Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina. more
Time Frame | BCRX | Sector | S&P500 |
---|---|---|---|
1-Week Return | 4.29% | -0.94% | -2.6% |
1-Month Return | 7.02% | -5.08% | -1.08% |
3-Month Return | -0.13% | -10.62% | 3.45% |
6-Month Return | 24.08% | -6.18% | 8.57% |
1-Year Return | 27.96% | 1.98% | 24.3% |
3-Year Return | -44.11% | -0.93% | 25.58% |
5-Year Return | 153.42% | 33.84% | 84.07% |
10-Year Return | -29.72% | 102.52% | 185.12% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 48.84M | 17.81M | 157.17M | 270.83M | 331.41M | [{"date":"2019-12-31","value":14.74,"profit":true},{"date":"2020-12-31","value":5.37,"profit":true},{"date":"2021-12-31","value":47.42,"profit":true},{"date":"2022-12-31","value":81.72,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | 4.10M | 1.68M | 7.26M | 6.59M | 4.66M | [{"date":"2019-12-31","value":56.46,"profit":true},{"date":"2020-12-31","value":23.07,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":90.78,"profit":true},{"date":"2023-12-31","value":64.17,"profit":true}] |
Gross Profit | 44.73M | 16.14M | 149.91M | 264.23M | 326.75M | [{"date":"2019-12-31","value":13.69,"profit":true},{"date":"2020-12-31","value":4.94,"profit":true},{"date":"2021-12-31","value":45.88,"profit":true},{"date":"2022-12-31","value":80.87,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | 91.60% | 90.59% | 95.38% | 97.57% | 98.59% | [{"date":"2019-12-31","value":92.91,"profit":true},{"date":"2020-12-31","value":91.88,"profit":true},{"date":"2021-12-31","value":96.74,"profit":true},{"date":"2022-12-31","value":98.96,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Expenses | 144.19M | 190.89M | 327.63M | 412.67M | 430.46M | [{"date":"2019-12-31","value":33.5,"profit":true},{"date":"2020-12-31","value":44.35,"profit":true},{"date":"2021-12-31","value":76.11,"profit":true},{"date":"2022-12-31","value":95.87,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (99.45M) | (174.76M) | (177.72M) | (148.44M) | (103.71M) | [{"date":"2019-12-31","value":-9945500000,"profit":false},{"date":"2020-12-31","value":-17475700000,"profit":false},{"date":"2021-12-31","value":-17772000000,"profit":false},{"date":"2022-12-31","value":-14843500000,"profit":false},{"date":"2023-12-31","value":-10370900000,"profit":false}] |
Total Non-Operating Income/Expense | (19.40M) | (13.14M) | (63.32M) | (189.91M) | (218.62M) | [{"date":"2019-12-31","value":-1940100000,"profit":false},{"date":"2020-12-31","value":-1313800000,"profit":false},{"date":"2021-12-31","value":-6332100000,"profit":false},{"date":"2022-12-31","value":-18991300000,"profit":false},{"date":"2023-12-31","value":-21861800000,"profit":false}] |
Pre-Tax Income | (108.90M) | (182.81M) | (181.81M) | (244.38M) | (226.23M) | [{"date":"2019-12-31","value":-10889700000,"profit":false},{"date":"2020-12-31","value":-18281400000,"profit":false},{"date":"2021-12-31","value":-18180900000,"profit":false},{"date":"2022-12-31","value":-24438400000,"profit":false},{"date":"2023-12-31","value":-22622900000,"profit":false}] |
Income Taxes | 11.17M | 13.75M | 2.25M | 2.73M | 310.00K | [{"date":"2019-12-31","value":81.2,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":16.38,"profit":true},{"date":"2022-12-31","value":19.87,"profit":true},{"date":"2023-12-31","value":2.25,"profit":true}] |
Income After Taxes | (120.06M) | (196.57M) | (184.06M) | (247.12M) | (226.54M) | [{"date":"2019-12-31","value":-12006500000,"profit":false},{"date":"2020-12-31","value":-19656700000,"profit":false},{"date":"2021-12-31","value":-18406200000,"profit":false},{"date":"2022-12-31","value":-24711700000,"profit":false},{"date":"2023-12-31","value":-22653900000,"profit":false}] |
Income From Continuous Operations | (108.90M) | (192.23M) | (184.06M) | (247.12M) | (236.35M) | [{"date":"2019-12-31","value":-10889700000,"profit":false},{"date":"2020-12-31","value":-19223400000,"profit":false},{"date":"2021-12-31","value":-18406200000,"profit":false},{"date":"2022-12-31","value":-24711700000,"profit":false},{"date":"2023-12-31","value":-23634900000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (120.06M) | (196.57M) | (184.06M) | (247.12M) | (226.54M) | [{"date":"2019-12-31","value":-12006500000,"profit":false},{"date":"2020-12-31","value":-19656700000,"profit":false},{"date":"2021-12-31","value":-18406200000,"profit":false},{"date":"2022-12-31","value":-24711700000,"profit":false},{"date":"2023-12-31","value":-22653900000,"profit":false}] |
EPS (Diluted) | (0.98) | (1.08) | (1.03) | (1.33) | (0.99) | [{"date":"2019-12-31","value":-98,"profit":false},{"date":"2020-12-31","value":-108,"profit":false},{"date":"2021-12-31","value":-103,"profit":false},{"date":"2022-12-31","value":-133,"profit":false},{"date":"2023-12-31","value":-99,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
BCRX | |
---|---|
Cash Ratio | 2.15 |
Current Ratio | 2.78 |
Quick Ratio | 2.73 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
BCRX | |
---|---|
ROA (LTM) | -4.25% |
ROE (LTM) | -1925.37% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
BCRX | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 1.95 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | -0.95 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
BCRX | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 3.80 |
P/B | 56.59 |
Price/FCF | 192 |
EV/R | 4.96 |
EV/Ebitda | NM |
PEG | NM |
BioCryst Pharmaceuticals Inc (BCRX) share price today is $7.78
Yes, Indians can buy shares of BioCryst Pharmaceuticals Inc (BCRX) on Vested. To buy BioCryst Pharmaceuticals Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in BCRX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of BioCryst Pharmaceuticals Inc (BCRX) via the Vested app. You can start investing in BioCryst Pharmaceuticals Inc (BCRX) with a minimum investment of $1.
You can invest in shares of BioCryst Pharmaceuticals Inc (BCRX) via Vested in three simple steps:
The 52-week high price of BioCryst Pharmaceuticals Inc (BCRX) is $8.88. The 52-week low price of BioCryst Pharmaceuticals Inc (BCRX) is $4.03.
The price-to-earnings (P/E) ratio of BioCryst Pharmaceuticals Inc (BCRX) is
The price-to-book (P/B) ratio of BioCryst Pharmaceuticals Inc (BCRX) is 56.59
The dividend yield of BioCryst Pharmaceuticals Inc (BCRX) is 0.00%
The market capitalization of BioCryst Pharmaceuticals Inc (BCRX) is $1.57B
The stock symbol (or ticker) of BioCryst Pharmaceuticals Inc is BCRX